Drugs Made In America Acquisition II Corp. (DMII) stock
DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.23−0.01 (-0.15%)
Close on Nov 18, 2026Market cap $140.15MP/E –Yield –
Drugs Made In America Acquisition II operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Drugs Made In America Acquisition II's operating cash flow for the twelve months ending Sep 30, 2026 was -$646.86K. For fiscal 2025 it was -$1.02M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.02M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$56.74K | – |
| Q2 FY2026 | Jun 30, 2026 | -$172.75K | – |
| Q1 FY2026 | Mar 31, 2026 | -$102.50K | – |
| Q4 FY2025 | Dec 31, 2025 | -$314.86K | – |
| Q3 FY2025 | Sep 30, 2025 | -$690.73K | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.60K | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.04K | – |
See a number that looks wrong?